Subpart E in Section 312 of the Code of Federal Regulations establishes procedures to expedite the development,
evaluation, and marketing of new therapies intended to treat people with life-threatening and severely-debilitating
illnesses, especially where no satisfactory alternatives exist (Federal Register, October 21, 1988).
